Roche has a handful of key Phase III readouts from potential blockbusters this year, with its oral SERD, giredestrant, expected to be the centerpiece of a future breast cancer franchise.

CEO Thomas Schinecker is signalling that historic investment in Switzerland cannot be sustained unless the country makes its investment and pricing environment more pharma-friendly.

The Swiss company’s strategy head, Ronny Gal, joins calls for improvement in US competitiveness, as McKinsey highlights competition from other Asian countries beyond China.

The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.

Companies requiring follow-on financing were particularly hit in 2025, but the first signs of ‘pension power’ has given the UK sector hope of more investment.

Deal Snapshot: BMS is casting a broad net in oncology as it looks to replace its aging blockbuster Opdivo with a variety of novel cancer therapies.